Status:
COMPLETED
Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy
Lead Sponsor:
West China Hospital
Conditions:
Primary Liver Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Patients who meet the enrollment criteria will be randomized 1:1 to either the lidocaine or the placebo group. In the lidocaine group, at the end of the induction of general anesthesia, a bolus injec...
Detailed Description
Patients who meet the enrollment criteria will be randomized 1:1 to either the lidocaine or the placebo group. In the lidocaine group, at the end of the induction of general anesthesia, a bolus injec...
Eligibility Criteria
Inclusion
- Age: 18-80 years old
- American Society of Anesthesiologists(ASA) Ⅰ～III
- patients scheduled for elective hepatectomy
Exclusion
- • body weight \< 40 kg or \>100 kg; metastases occurring in other distant organs; severe hepatic insufficiency (aspartate aminotransferase or alanine transaminase or bilirubin \> 2.5 times the upper limit of normal), renal impairment (creatinine clearance \< 60 ml/min); cardiac rhythm disorders or systolic heart failure (second-and third-degree heart block, ejection fraction \< 50%); with allergies to any of the trial drugs; inability to comprehend numeric rating scale.
Key Trial Info
Start Date :
February 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 27 2022
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT04295330
Start Date
February 27 2020
End Date
May 27 2022
Last Update
August 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital
Chengdu, Sichuan, China, 610041